MDJunction - People Helping People
 
Ask a Question
03/06/2012 02:45 AM

OSTEOPOROSIS articles ongoing; men & women(page 4)

Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

Many don't stick to bone drugs, despite counseling

Monday, February 27, 2012

By Frederik Joelving

NEW YORK (Reuters Health) -

People with the bone-thinning condition osteoporosis often skip the drugs they are prescribed, and telephone counseling does little to change that, according to new research.

Researchers said osteoporosis is involved in more than two million fractures a year in the U.S., racking up medical costs of $19 billion.

In addition to exercise and a healthy diet with enough calcium and vitamin D, as well as measures to prevent falls, medications may reduce the risk of broken bones -- which can take a serious toll on the health of old people.

For people at high risk, bone drugs such as bisphosphonates may cut the yearly fracture risk from five percent to three percent, said Dr. Daniel Solomon of Brigham and Women's Hospital in Boston.

But people often stop taking the medications, added Solomon, also of Harvard Medical School.

"It's the problem with all chronic conditions," he told Reuters Health. "Drugs for asymptomatic chronic conditions are universally poorly adhered to."

Some 10 million Americans currently suffer from bone thinning, according to the National Osteoporosis Foundation. The majority are postmenopausal women.

Bone drugs include Merck's Fosamax, Roche's Boniva, Novartis's Reclast and Warner Chilcott's Actonel.

To see if they could convince people to take their drugs, Solomon and his colleagues divided more than 2,000 men and women with osteoporosis into two groups.

The participants were all on Medicare, the government's health insurance for the elderly, and got their meds for a co-pay of no more than a few dollars.

All of them received fall-prevention lifestyle tips in the mail from the researchers, and one group also had about eight counseling sessions over the phone.

During those sessions, trained counselors tried to identify why people skipped their drugs and to motivate them to get back on the treatment. The intervention ended up costing about $281 per patient, including training of the counselors.

After one year, there was little difference between the two groups.

Those who got counseling filled their prescriptions 49 percent of the time, while the others did so 41 percent of the time, based on claims data. That gap was too small to be reliable, statistically speaking.

The researchers didn't find any differences in how many people broke a bone or reported falls, either.

According to Solomon, people who skipped their medicine often said they had forgotten about it, didn't like the way it made them feel or didn't think they needed it.

Still, Solomon, whose findings appear in the Archives of Internal Medicine, wasn't willing to give up on counseling.

"It would be overstating the data to say that we should use this. What I'm saying is you don't want to throw the baby out with the bathwater," he said. "I think that counseling is something we need to continue to examine."

Researchers have been experimenting with a lot of ways to get people to take their drugs, including beeping pill caps and financial incentives, Solomon added. But the results have often been disappointing.

"At this point there really aren't any proven interventions," he said.

In an editorial, Dr. Seth Berkowitz and Dr. Kirsten Johansen of the University of California, San Francisco, say behavior change is an increasingly important part of medicine as chronic diseases continue rise.

"There is likely no 'magic bullet' in the behavior change arsenal in general or for increasing treatment adherence specifically," they write. "This does not mean, however, that the effects may not be clinically significant."

SOURCE: http://bit.ly/yMrnv4 Archives of Internal Medicine, February 27, 2012.

http://www.nlm.nih.gov/medlineplus/news/ fullstory_122372.html

(c) Copyright Thomson Reuters 2012.

Reply

03/06/2012 02:47 AM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

glucocorticoid-induced osteoporosis 2 page article online

http://www.hormone.org/Resources/upload/Glucocorticoid- induced-Osteoporosis-Web-Bilingual.pdf

bettyg


03/06/2012 03:35 AM
VicMac
VicMac  
Posts: 1659
Senior Member

Betty, some good articles here. Thanks! I can throw in some info my Kaiser naturopath gave me on osteoporosis. I am actually trying these things now.

An herb called Devil's Backbone is supposed to help regenerate bone. DHEA also.

Strontium. Prunes and plums. Also vitamin K.

I am taking a couple of these things right now, will let everybody know how it is working later on when I test again.

Started Fosamax, but dont like how I feel on it at all. So think I will hold off on it.

Post edited by: VicMac, at: 03/06/2012 03:36 AM


03/13/2012 01:52 AM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

Lower Your Risk for Osteoporosis

Here are factors you can control

By Diana Kohnle

Tuesday, March 6, 2012

(HealthDay News) -- Some risk factors for osteoporosis you can't control -- such as your age, heritage and family history of the brittle bones condition.

But the womenshealth.gov website says there are risk factors than you can control, including:

•Getting plenty of calcium in your diet each day.

•Getting plenty of daily vitamin D.

•Eating a healthy, balanced and nutrient-rich diet.

•Getting plenty of weight-bearing exercise.

•Avoiding smoking and drinking alcohol in moderation.

•Taking medication to reduce bone loss, if your doctor recommends it.

http://www.nlm.nih.gov/medlineplus/news/ fullstory_122622.html

Copyright (c) 2012 HealthDay. All rights reserved.


03/30/2012 11:55 PM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

FDA approves first Boniva (ibandronate) tablet generics to treat or prevent osteoporosis

For Immediate Release: March 19, 2012

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

The U.S. Food and Drug Administration today approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.

The most common type of bone disease, osteoporosis, is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures of the hip, spine, and wrist.

Ibandronate is in a class of medications called bisphosphonates that help increase bone mass and reduce the chance of having a spinal fracture.

According to the National Institutes of Health, in the United States more than 40 million people either already have osteoporosis or are at high risk due to low bone mass.

“Men as well as women are affected by osteoporosis, a disease that can be prevented and treated,” said Keith Webber, Ph.D., deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research.

“For people who must manage their health conditions over time, it is important to have affordable treatment options.”

Generic drugs approved by FDA have the same high quality and strength as brand-name drugs and provide a lower cost alternative. The generic manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Apotex Inc., Orchid Healthcare, and Mylan Pharmaceuticals Inc. are the manufacturers that have gained FDA approval to make generic 150 milligram ibandronate tablets.

An FDA-required Medication Guide will be given to patients and caregivers when ibandronate is dispensed, describes the risks and adverse reactions people should be mindful of when using the drug. Ibandronate can cause serious side effects including: esophagus problems; low calcium levels in the blood; bone, joint, or muscle pain; severe jaw bone problems; and unusual thigh bone fractures.

In the clinical trials for Boniva, the most commonly observed adverse reactions were: back pain, indigestion (dyspepsia), pain in extremity, diarrhea, headache, and muscle pain (myalgia).

Information about the availability of generic ibandronate can be obtained from the manufacturers.

For more information:

FDA: Understanding Generic Drugs1

National Institutes of Health: Osteoporosis

2

Information on specific drug products, Drugs@FDA

3

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.

The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

#Links on this page:

/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/ UnderstandingGenericDrugs/default.htm

http://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

Page Last Updated: 03/19/2012

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm296488

U.S. Food and Drug Administration

10903 New Hampshire Avenue

Silver Spring, MD 20993

Ph. 1-888-INFO-FDA (1-888-463-6332)


04/02/2012 09:44 PM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

How Often Should Women Have Bone Tests?

Experts say that older women should have regular bone density tests to screen for osteoporosis. But it's been unclear how often to repeat the tests.

A new study suggests that women with healthy bone density on their first test might wait 15 years before getting rescreened.

More than 40 million people nationwide either have osteoporosis or are at increased risk for broken bones because of low bone mineral density (osteopenia).

Osteoporosis is often called a “silent disease” because it usually develops slowly and without symptoms until a fracture occurs.

When early screening detects low bone mineral density, patients can try lifestyle changes or therapies to protect their bones.

To help develop guidance on how often to repeat bone density tests, NIH-funded scientists studied nearly 5,000 women ages 67 and older.

When the study began, none of the women had osteoporosis, hip or spine fractures or past treatment with osteoporosis medications.

The researchers found that less than 1% of women who initially had normal bone mineral density went on to develop osteoporosis during the study.

Only 5% of those with mildly low bone density at the start made the transition to osteoporosis.

“If a woman's bone density at age 67 is very good, then she doesn't need to be rescreened in 2 years or 3 years, because we're not likely to see much change,” says lead researcher Dr. Margaret Gourlay of the University of North Carolina at Chapel Hill.

“Our study found it would take about 15 years for 10% of women with normal or mildly low bone mineral density to develop osteoporosis. That was longer than we expected, and it's great news for this group of women.”

Age, past fractures, medications and specific diseases can increase osteoporosis risk. These factors also affect how often a woman should be tested.

http://newsinhealth.nih.gov/issue/Mar2012/Capsule1

CONTACT US

NIH Office of Communications

and Public Liaison

Building 31, Room 5B64

Bethesda, MD 20892-2094

nihnewsinhealth@od.nih.gov

Tel: 301-435-7489 Fax: 301-480-4026

no copyright shown


04/10/2012 12:59 AM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

Osteoporosis Drugs, Oral bisphosphonates, such as Fosamax and Actonel May Lead to Eye Trouble: Study

Researchers say they found risk for anterior uveitis and scleritis, diseases that can cause impairment

By Robert Preidt

Monday, April 2, 2012

MONDAY, April 2 (HealthDay News) --

First-time users of osteoporosis drugs called oral bisphosphonates may be at increased risk for serious inflammatory eye disease, a new study contends.

Oral bisphosphonates, such as Fosamax and Actonel, are the most commonly prescribed class of drugs to prevent or slow osteoporosis, a disease that causes very weak bones.

Previous studies have linked the drugs to problems such as unusual fractures, irregular heartbeat and esophageal and colon cancer.

In addition, some case reports have shown an association between the drugs and inflammatory eye diseases -- anterior uveitis and scleritis -- that can cause serious vision impairment.

In this new study, Canadian researchers compared nearly 11,000 first-time users of oral bisphosphonates and more than 920,000 non-users.

First-time users had incidence rates of 29 per 10,000 person-years for uveitis and 63 per 10,000 person-years for scleritis, compared with 20 per 10,000 and 36 per 10,000, respectively, for non-users.

Per-person years are determined by multiplying the number of participants by the number of years the drugs are taken.

The study is published April 2 in the journal CMAJ.

"We found that first-time users of bisphosphonates are at an increased risk of scleritis and uveitis," wrote Dr. Mahyar Etminan, of the Child and Family Research Institute and the Department of Medicine at the University of British Columbia, and colleagues in a journal news release.

"Our study highlights the need for clinicians to inform their patients about the signs and symptoms of scleritis and uveitis, so that prompt treatment may be sought and further complications averted," they added.

SOURCE: CMAJ, news release, April 2, 2012

http://www.nlm.nih.gov/medlineplus/news/ fullstory_123631.html

Copyright (c) 2012 HealthDay. All rights reserved.


04/17/2012 03:13 AM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

Certain Genetic Regions May Be Tied to Osteoporosis

But it's too early to use data to predict who will or will not develop weaker bones

By Mary Elizabeth Dallas

Sunday, April 15, 2012

SUNDAY, April 15 (HealthDay News) --

A large international group of researchers has identified 32 new genetic regions linked to fractures and osteoporosis.

Variations in these regions could offer protection from, or greater risk for, bone-weakening disease, the investigators reported in a new study published in the April 15 online edition of Nature Genetics.

The study authors added that their findings could lead to the development of new osteoporosis drugs.

"We're learning that the genetic architecture of disease is very complex," one of the study's authors and the methodological leader of the consortium, Dr. John Ioannidis, chief of the Stanford Prevention Research Center, said in a university news release.

The research, which involved 17 studies that compared common genetic variants in more than 100,000 people, pinpointed six regions linked to risk of fractures of the femur (thigh bone) or lower back.

The study authors pointed out, however, that it would still be difficult to predict who is at greater risk for bone disease. People with the highest number of variants associated with decreased bone mineral density were only about one and a half times more likely than people with an average number of variants to have osteoporosis. The risk for fractures was only slightly higher.

Meanwhile, compared to those with the fewest variants, people with the most variants were still just three to four times more likely to have had fractures and lower bone mineral density, the study revealed.

"As a result, the next step of incorporating this information into basic patient care is not clear," Ioannidis concluded. "Each variant conveys a small quantum of risk or benefit. We can't predict exactly who will or won't get a fracture."

The authors noted, however, that by identifying some previously unsuspected pathways involved in bone health, their research could lead to the development of new anti-osteoporosis drugs. But even larger studies are needed to identify all of the genes critical to fighting bone disease, they added.

"We saw many of these regions and genes clustering within specific types of pathways, which suggests certain disease mechanisms. It certainly wouldn't be unexpected to eventually identify many more genetic regions involved in the regulation of osteoporosis and fracture risk," Ioannidis said.

"In reality, there may be 500 or more gene variants regulating osteoporosis. To find all of them, we'll need to study millions of patients. Is this unrealistic?

I don't think so. Sooner or later this will be feasible," he added.

SOURCE: Stanford University School of Medicine, news release, April 15, 2012

http://www.nlm.nih.gov/medlineplus/news/ fullstory_124122.html

Copyright (c) 2012 HealthDay. All rights reserved.


04/24/2012 12:12 AM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

12 PAGES informative listing foods, conditions, charts

http://www.iofbonehealth.org/sites/default/files/PDFs/ good_nutrition_for_healthy_bones.pdf

bettyg,


05/06/2012 10:51 PM
Bettyg
 
Posts: 33531
VIP Member
I'm an Advocate

Nutritional Approaches for Beating Osteoporosis

Nutritional approaches for improving bone health

Published on February 16, 2012

by Jacob Teitelbaum, MD in Complementary Medicine

With new studies showing that long-term use of osteoporosis medications like Fosamax offer no continuing benefit after five years[1], people are wondering what to do to improve their bone density.

And a lot of people should wonder. Thirty-five million American women and 17 million men have low bone density: thinning, weakening and breakable bones.

One out of two women will have an osteoporotic fracture in their lifetime.

The good news is that there are excellent nutritional approaches that dramatically and safely increase bone density (and health), and help prevent osteoporosis.

The bad news? Most physicians aren't familiar with those approaches!

Fortunately, knowledge is power. And this article provides the knowledge you need. Let's start by examining five common beliefs about bone health.

I'll tell you which ones are TRUE, and which are myths that have been BUSTED—and discuss the very best strategies for building bone.

Five Common Beliefs About Bone Health

1. Antacids are good for strong bones, because they contain lots of calcium.

BUSTED!

An analysis of data from the massive Women's Health Initiative linked calcium supplements to a 31% increased risk of heart attacks[2].

And a new study from Swedish researchers shows that only intakes below 750 mg of calcium a day put a person at increased risk for fractures—while intakes above 1,100 mg might increase risk[3]!

In other words, supplementing your diet with high doses of calcium may do you more harm than good!

BEST STRATEGY:

Regularly eat calcium-rich foods like leafy greens, fatty fish with bones (such as sardines and salmon) and dairy products.

Keep supplementation of calcium (including antacids) to a minimum—no more than 500 to 600 mg daily.

(For more info on calcium's downside, see the Research Briefs section of my February 15, 2012 newsletter.)

If taking a calcium supplement, be sure it also contains magnesium and vitamin D.

2. Avoid sunshine, because even though it raises levels of bone-building vitamin D, it needs to be avoided because of melanoma, a deadly skin cancer.

BUSTED!

It is unlikely that most of the increase in melanoma rates is being caused by an increased exposure to sun.

Most melanomas are not in sun-exposed areas. They are under our clothes.

If there is an increase in rates of melanoma, it's more likely to occur because of a fatty, salty, sugary diet; an environment saturated with toxic chemicals; and a population that is sleep-deprived—all resulting in weakened immune systems.

The real cancer problem is lack of vitamin D, which study after study links to the development of cancer.

In fact, it's estimated that the vitamin-D depriving advice to avoid sunshine doesn't prevent cancer. In fact it causes an estimated 145,000 unnecessary cancer deaths every year[4]!

BEST STRATEGY:

Avoid sunburn, not sunshine. Go for at least a 30-minute outdoor walk several times a week, particularly during the summer months.

And don't wear sunblock unless you're out long enough to sunburn. Both sunlight exposure and walking help build bones.

3. The longer you use osteoporosis medications, the stronger your bones.

BUSTED!

New research shows that taking Fosamax for more than five years may actually weaken the crystalline structure of bones, resulting in bones that are less elastic and therefore more fracture-prone[5].

BEST STRATEGY:

If you must take Fosamax, take it with vitamin D—a strategy that makes it five times more likely the drug will effectively build bones[6].

BETTYG NOTE: LYME/CO-INFECTION PATIENTS SHOULD NOT TAKE FOXAMAX; IT WILL EAT AWAY YOUR JAW BONES!! 2 lyme patients both had to have their jaws replaced the same summer i talked with them!!

4b]. You can literally "walk away" from bone fracture risk.

TRUE![/b]

Dozens of studies show that regular walking builds bone. One of the most recent showed that walking or jogging three times a week increased several biomarkers of bone density[7].

Even better is that those who exercised and took 1,000 mg a day of omega-3 fatty acids (fish oil) had even healthier levels of those biomarkers than people who just exercised.

BEST STRATEGY: A brisk, 30-minute walk, at least three times a week, along with a fish oil supplement.

5. Natural, nutritional approaches for helping prevent osteoporosis are an unproven scam.

BUSTED!

And busted over and over again. For example, the mineral strontium has been shown in many studies to protect bone.

In one of the most recent, researchers from Belgium analyzed bone strength in osteoporotic women who had been treated for a decade with strontium and found a 35% reduced risk of spinal fractures and a 38% reduced risk of non-spinal fractures[8].

In another recent study published in the January 2012 edition of Osteoporosis International, strontium outperformed Fosamax in building bones[9].

Another review of dozens of studies with thousands of patients found strontium to be very effective and safe in long-term treatment of osteoporosis[10].

So much for the scam!

BEST STRATEGY:

Take 340 to 680 mg of strontium daily.

This is best combined with other bone-building nutrients such as vitamins D and K, magnesium, and Boron (strontium absorption is modestly improved by taking it at a different time of day than calcium and vitamin D).

For a collection of articles (and a video) with more ideas on the best ways to beat osteoporosis, see Health A-Z: Osteoporosis.

References

1. "Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis." Lisa-Ann Fraser, Kelly N Vogt, Jonathan D Adachi, and Lehana Thabane. Ther Clin Risk Manag. 2011; 7: 157166. Published online 2011 May 9. doi: 10.2147/TCRM.S19385

2. "Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis." Bolland MJ, et al. BMJ 2011; DOI: doi:10.1136/bmj.d2040.

3. "Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study." Warensjo E, et al. BMJ. 2011;342:d1473.

4. "What is the Dose-Response Relationship between Vitamin D and Cancer Risk?" Garland CF, et al. Nutrition Reviews, August 2007(II): S91S95.

5. "Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization." Bala Y, et al. Journal of Bone and Mineral Research, 2011 Dec 20. doi: 10.1002/jbmr.1501 [pub ahead of print]

6. "The 25(OH)D level needed to maintain a favorable bisphosphonate response is (greater than or equal to) 33 ng/ml." Carmel AS, et al. Osteoporosis International. 2012 Jan 12. [Epub ahead of print]

7. "Long-term aerobic exercise and omega-3 supplementation modulate osteoporosis through inflammatory mechanisms in post-menopausal women: a randomized, repeated measures study." Tartibian B et al, Nutrition & Metabolism. 2011 Oct 15;8:71.

8. "Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis." Reginister JY, et al. Osteoporosis International. 2011 Nov 29 [Epub ahead print]

9. "Effects of strontium ranelate and aledronate on bone microstructure in women with osteoporosis. Results of a 2-year study." Rizzoli R, et al. Osteoporosis International. 2012 Jan;23(1):305-15. Epub 2011 Sep 10.

10. "Strontium Ranelate: Long-term Efficacy Against Vertebral, Nonvertebral and Hip Fractures in Patients With Postmenopausal Osteoporosis." Jean-Yves Reginster; Mickael Hiligsmann; Olivier Bruyere.Posted: 07/29/2010; Ther Adv Musculoskel Dis. 2010;2(3):133-143

Have a comment? Start the discussion here!

Tags: calcium supplements, dairy products, fatty fish, health initiative, heart attacks, intakes, knowledge is power, leafy greens, osteoporosis, sardines, swedish researchers

Jacob Teitelbaum, M.D., internist and author of From Fatigued to Fantastic!, researches treatments for Chronic Fatigue Syndrome and fibromyalgia.

http://www.psychologytoday.com/blog/complementary-medicine/ 201202/nutritional-approaches-beating-osteoporosis

© Copyright 1991-2012

Sussex Publishers, LLC

Post edited by: Bettyg, at: 05/06/2012 11:00 PM

Reply

Share this discussion with your friends:
<< Start < Prev 4 Next > End >>


Disclaimer: The information provided in MDJunction is not a replacement for medical diagnosis, treatment, or professional medical advice.
In case of EMERGENCY call 911 or 1.800.273.TALK (8255) to the National Suicide Prevention Lifeline. Read more.
Contact Us | About Us
Copyright (c) 2006-2014 MDJunction.com All Rights Reserved